Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

I. Mehmi · SciRah

Researcher profile · Semantic Scholar

I. Mehmi

Share profile

I. Mehmi — researcher profile on SciRah

h-index: 24
Works: 93
Citations: 2,174

Most-cited papers

Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
J. Menéndez, L. Vellon, I. Mehmi, Bharvi P Oza +3 more
2004Proceedings of the National Academy of Sciences of the United States of America349 citations Open access
Semantic Scholar
A novel CYR61-triggered ‘CYR61-αvβ3 integrin loop’ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway
J. Menéndez, L. Vellon, I. Mehmi, Poh K. Teng +2 more
2005Oncogene152 citations Open access
Semantic Scholar
Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
J. Menéndez, I. Mehmi, E. Atlas, R. Colomer +1 more
2004International Journal of Oncology139 citations
Semantic Scholar
Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo.
E. Atlas, M. Cardillo, I. Mehmi, Hengameh Zahedkargaran +2 more
2003Molecular Cancer Research128 citations
Semantic Scholar
The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives.
J. Menéndez, I. Mehmi, D. Griggs, R. Lupu
2003Endocrine-Related Cancer127 citations Open access
Semantic Scholar
Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer
Miaw-Sheue Tsai, Lisa A. Shamon-Taylor, I. Mehmi, Careen K. Tang +1 more
2003Oncogene126 citations Open access
Semantic Scholar
Pharmacological inhibition of fatty acid synthase (FAS): A novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her‐2/neu (erbB‐2) oncogene‐induced malignant transformation
Javier A. Menendez, I. Mehmi, Vishal A. Verma, Poh K. Teng +1 more
2004Molecular Carcinogenesis86 citations
Semantic Scholar
Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel me
J. Menéndez, S. Ropero, I. Mehmi, E. Atlas +2 more
2004International Journal of Oncology85 citations
Semantic Scholar
Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
J. Menéndez, I. Mehmi, R. Lupu
2006Journal of Clinical Oncology77 citations Open access
Semantic Scholar
Expression and regulation of Cyr61 in human breast cancer cell lines
Miaw-Sheue Tsai, Daphne F Bogart, P-A Li, I. Mehmi +1 more
2002Oncogene76 citations
Semantic Scholar
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
F. Dimitriou, K. Namikawa, I. Reijers, E. Buchbinder +42 more
2022Annals of Oncology65 citations Open access
Semantic Scholar
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
P. Bhave, T. Ahmed, S. Lo, A. Shoushtari +43 more
2022Journal for ImmunoTherapy of Cancer63 citations Open access
Semantic Scholar
Black cohosh, a menopausal remedy, does not have estrogenic activity and does not promote breast cancer cell growth.
R. Lupu, I. Mehmi, E. Atlas, M.-S. Tsai +5 more
2003International Journal of Oncology62 citations
Semantic Scholar
Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma
M. Milhem, R. Gonzales, T. Medina, J. Kirkwood +11 more
2018Clinical Trials54 citations
Semantic Scholar
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial
R. Dummer, Caroline Robert, R. Scolyer, J. Taube +17 more
2025Nature Medicine47 citations Open access
Semantic Scholar
Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells
J. Menéndez, Bharvi P Oza, E. Atlas, Vishal A. Verma +2 more
2004Oncogene44 citations Open access
Semantic Scholar
Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in cancer patients
Jane C. Figueiredo, N. Merin, O. Hamid, So-Yung Choi +29 more
2021Cancer Research41 citations Open access
Semantic Scholar
Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
J. Menéndez, A. Papadimitropoulou, Travis Vander Steen, E. Cuyás +6 more
2021Cancers39 citations Open access
Semantic Scholar
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
Omid Hamid, K. Lewis, A. Weise, M. McKean +28 more
2024Journal of Clinical Oncology32 citations Open access
Semantic Scholar
Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
J. Menéndez, I. Mehmi, A. Papadimitropoulou, Travis Vander Steen +6 more
2020International Journal of Molecular Sciences27 citations Open access
Semantic Scholar
Endogenous aryl hydrocarbon receptor promotes basal and inducible expression of tumor necrosis factor target genes in MCF-7 cancer cells
Travis B. Salisbury, J. Tomblin, D. Primerano, G. Bošković +7 more
2014Biochemical Pharmacology26 citations Open access
Semantic Scholar
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma
M. Milhem, Y. Zakharia, D. Davar, E. Buchbinder +20 more
202025 citations Open access
Semantic Scholar
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
S. Jacques, Janet McKeown, P. Grover, Douglas B. Johnson +35 more
2024European Journal of Cancer24 citations
Semantic Scholar
Eflapegrastim, a Long‐Acting Granulocyte‐Colony Stimulating Factor for the Management of Chemotherapy‐Induced Neutropenia: Results of a Phase III Trial
L. Schwartzberg, G. Bhat, J. Peguero, R. Agajanian +8 more
2020The Oncologist24 citations Open access
Semantic Scholar
Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma.
J. Weber, A. Puranik, Teruyuki Mitzutani, Tomoaki Muramatsu +14 more
2024Journal of Clinical Oncology20 citations Open access
Semantic Scholar
Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
J. Menéndez, I. Mehmi, R. Lupu
2005International Journal of Oncology20 citations
Semantic Scholar
A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity
E. Atlas, K. Bojanowski, I. Mehmi, R. Lupu
2003Oncogene20 citations
Semantic Scholar
Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma
R. Dummer, C. Robert, R. Scolyer, J. Taube +15 more
2023Cancer Research17 citations
Semantic Scholar
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.
F. Dimitriou, M. Orloff, Erica C. Koch Hein, P. Cheng +20 more
2024European Journal of Cancer13 citations Open access
Semantic Scholar
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
P. Grover, S. Lo, I. Li, A. Kuijpers +64 more
2025Annals of Oncology12 citations Open access
Semantic Scholar
Abstract CT004: Intratumoral (IT) MEDI1191 + durvalumab (D): Update on the first-in-human study in advanced solid tumors
E. Castañón, D. Zamarin, B. Carneiro, T. Marron +13 more
2023Cancer Research12 citations
Semantic Scholar
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
V. Sahai, M. Rothe, P. Mangat, E. Garrett-Mayer +15 more
2024JCO Precision Oncology11 citations Open access
Semantic Scholar
Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study
G. Srkalović, M. Rothe, P. Mangat, E. Garrett-Mayer +15 more
2024JCO Precision Oncology11 citations
Semantic Scholar
Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.
I. Mehmi, O. Hamid, F. Hodi, M. Vassalo +7 more
202110 citations
Semantic Scholar
A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma.
J. Mehnert, I. Mehmi, Judith D. Goldberg, Maya Dimitrova +15 more
2025Journal of Clinical Oncology8 citations
Semantic Scholar
A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.
O. Hamid, M. Gutierrez, I. Mehmi, M. Dudzisz-Śledź +3 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
Abstract CT183: First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors
B. Carneiro, D. Zamarin, T. Marron, I. Mehmi +16 more
2022Cancer Research7 citations
Semantic Scholar
Metastatic Sarcomatoid Carcinoma of the Small Intestine: a Case Report of Rare Tumor with Literature Review
Yousef Khelfa, M. Alsharedi, I. Mehmi, Ali Raufi +3 more
2015Journal of Gastrointestinal Cancer7 citations
Semantic Scholar
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients
T. Lim, Kamaneh Montazeri, E. Wehrenberg-Klee, Antoine Desilets +14 more
2025The Oncologist6 citations
Semantic Scholar
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade–resistant melanoma: Final analysis from a phase 1b study
M. Milhem, Y. Zakharia, D. Davar, Elizabeth I. Buchbinder +19 more
2025Cancer6 citations Open access
Semantic Scholar
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
Sylvia M. Lee, Omid Hamid, R. Jotte, Y. Zakharia +13 more
2024Clinical Cancer Research6 citations Open access
Semantic Scholar
950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma
J. Kirkwood, Y. Zakharia, D. Davar, E. Buchbinder +20 more
2021Journal for ImmunoTherapy of Cancer6 citations Open access
Semantic Scholar
Abstract CT032: CMP-001 demonstrates improved response in noninflamed anti-PD-1 refractory melanoma and response is associated with serum CXCL10
J. Luke, R. Bao, J. Kirkwood, Y. Zakharia +19 more
2021Clinical Trials6 citations
Semantic Scholar
Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.
I. Mehmi, Jordan Hill
20186 citations
Semantic Scholar
International Congress on Hormonal Steroids and Hormones and Cancer The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives
I. Mehmi, D. Griggs, R. Lupu
20036 citations
Semantic Scholar
Immunotherapy of cancer in the era of checkpoint inhibitor
I. Mehmi, O. Hamid
2021Clinical and Experimental Metastasis5 citations
Semantic Scholar
Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.
R. Govindan, A. Townsend, K. Miller, I. Mehmi +11 more
2021Journal of Clinical Oncology5 citations
Semantic Scholar
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study
J. S. Borgers, Douglas B. Johnson, E. Livingstone, D. Schadendorf +33 more
2025EClinicalMedicine3 citations Open access
Semantic Scholar
Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.
J. Thomas, J. Selfridge, C. Albany, Matthew H. Taylor +7 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
Low booster uptake in cancer patients despite health benefits
Jane C. Figueiredo, Julia A. Levy, So-Yung Choi, Alexander Xu +22 more
2023medRxiv3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Lupu×17
Invite
R. Lupu — researcher profile on SciRah
J. Menéndez×10
Invite
J. Menéndez — researcher profile on SciRah
E. Atlas×7
Invite
E. Atlas — researcher profile on SciRah
Omid Hamid×7
Invite
Omid Hamid — researcher profile on SciRah

×6

Invite

O. Hamid — researcher profile on SciRah

F. Dimitriou×5

Invite

F. Dimitriou — researcher profile on SciRah

Invite

A. Menzies — researcher profile on SciRah

Invite

M. Shaheen — researcher profile on SciRah

Invite

Y. Zakharia — researcher profile on SciRah

Invite

L. Vellon — researcher profile on SciRah

E. Buchbinder×4

Invite

E. Buchbinder — researcher profile on SciRah

Invite

C. Allayous — researcher profile on SciRah